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 ABSTRACT 
 
DAPSONE ACTIVATION OF CYP2C9 ALLELIC VARIANTS 
 
Matthew Aaron Hummel 
 
 
Studies have shown that CYP2C9.1 mediated metabolism of flurbiprofen and naproxen is 
activated by dapsone.  However, dapsone activation has not been studied in the allelic 
variant forms of CYP2C9.  Six concentrations of flurbiprofen (2-300 µM) or naproxen 
(10-1800 µM) were co-incubated with six concentrations of dapsone (0-100 µM) and 
with reconstituted, purified CYP2C9.1, CYP2C9.2 (R144C), CYP2C9.3 (I359L), or 
CYP2C9.5 (D360E), in order to assess degrees of activation.  Dapsone increased the 
efficicency (Vmax/Km) of flurbiprofen 4′-hydroxylation 690%, 3029%, 4600%, and 
2100% by CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5, respectively.  Dapsone 
increased the efficiency of naproxen demethylation 591%, 1400%, 1150%, and 2100%, 
by CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5, respectively.  Also, dapsone 
normalized naproxen’s kinetic profile from biphasic (CYP2C9.1 and CYP2C9.2) or 
linear (CYP2C9.3 and CYP2C9.5) to hyperbolic for all variant forms.   The amino acid 
substitutions of CYP2C9 allelic variants appear to affect the degree of dapsone 
activation. 
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CHAPTER I 
 
1. Introduction 
 2
 Cytochrome P450’s are a superfamily of mono-oxygenase enzymes that are 
responsible for the detoxification of exogenous as well as endogenous compounds, are 
found mainly in the liver, but are also present in other locations in the body, such as, the 
gut, skin, and lungs (Guengerich, 1995).  Of the CYP2C subfamily, CYP2C9 is the major 
isoform comprising roughly 20% of total liver P450 content (Guengerich, 1995).  As with 
other P450’s, CYP2C9 metabolizes a range of substrates, including S-warfarin, 
phenytoin, tolbutamide, and a number NSAIDS, including flurbiprofen, naproxen, and 
piroxicam (Leemann et al., 1993;Rettie et al., 1992;Rodrigues et al., 1996;Tracy et al., 
1996;Veronese et al., 1991b;Zhao et al., 1992).  To date, six allelic forms, including the 
most common or wild type, have been discovered.  Each of the five variants exhibits 
altered substrate metabolism, resulting in a decrease in the maximal rate of turnover 
and/or binding capacity.  These reductions in substrate turnover are particularly important 
when dealing with low therapeutic index drugs such as warfarin and phenytoin (Furuya et 
al., 1995;Hashimoto et al., 1996;Rettie et al., 1994).  The allelic variants differ from the 
wild type by only one amino acid residue, which occurs as a result of a single nucleotide 
polymorphism. 
 CYP2C9.1 is the wild type form, and so, is found most often in the population.  
The homozygous genotype, or *1*1, is found in roughly 66% of the Caucasian 
population (Lee et al., 2002).  This genotype is even more prevalent in the Asian and 
African-American population, being expressed in more than 90% of the population (Lee 
et al., 2002). 
 The CYP2C9.2 variant has a cysteine residue in place of an arginine residue at 
amino acid position 144 due to the substitution of a cytosine for a thymine at nucleotide 
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430 (Bhasker et al., 1997).  Approximately 20% of the Caucasian population are 
heterozygous, *1*2, with about 1% coding for the homozygous *2*2, and about 1% 
coding for *2*3 genotype (Lee et al., 2002).  So far, there have been no occurrences of 
the *2 allele discovered in Asian individuals (Lee et al., 2002).  About 5 % of the 
African-American population have been genotyped with a *2 allele (Dickmann et al., 
2001).  Although CYP2C9.2 has been shown to reduce the metabolism of some 
substrates, amino acid position 144 is not thought to be in the active site of the enzyme.  
Crespi and Miller have implicated this substitution in reducing the interaction of the P450 
with NADPH reductase, an essential protein necessary for the electron flow that is 
required for the oxidation of substrates (Crespi and Miller, 1997).  At pH 7.4, this effect 
may be due to the charged arginine residue making an electrostatic contact with the 
reductase, whereas the cysteine side chain is polar, but not charged.  A number of in-vitro 
studies have been performed to examine the effects of this amino acid substitution.  For 
example, Yamazaki and colleagues demonstrated that human liver microsomes taken 
from individuals genotyped heterozygous *1*2 had an intrinsic clearance for S-warfarin, 
diclofenac and flurbiprofen  that was 41%, 65%, and 36% of the wild type activity, 
respectively, with the difference being accounted for mainly by the differences in Vmax 
(Yamazaki et al., 1998).   The CYP2C9.2 variant has also been studied for its effects on 
in-vivo metabolism of CYP2C9 substrates.  A study conducted by Aithal et. al., showed 
evidence of lower warfarin dose requirements for patients genotyped with a CYP2C9*2 
allele than those with the wild type form (Aithal et al., 1999).  
 The CYP2C9.3 variant has probably the slightest amino acid difference, having a 
leucine residue in place of an isoleucine residue at amino acid position 359 as a result of 
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cytosine being in the place of adenine at nucleotide 1075 (Bhasker et al., 1997).  In the 
Caucasian population, about 10% of individuals are heterozygous, *1*3, while about 
0.5% are homozygous, *3*3 (Lee et al., 2002).  2.5% of the African-American 
population was genotyped as heterozygous *1*3 (Dickmann et al., 2001).  This variant 
has yet to be observed in Asian individuals (Lee et al., 2002). Amino acid position 359 is 
thought to be in substrate recognition site (SRS) 5 according to Gotoh and may have a 
role in substrate binding (Gotoh, 1992).  The change from isoleucine to leucine is not a 
major one, since they are isoforms.  The only difference between the two amino acids is 
the position of the methyl group on the side chain.  The change may alter the size of the 
binding pocket and cause differences in steric hinderance compared to the wild type 
protein or affect protein folding.  This variant has been shown to affect the metabolism of 
CYP2C9 substrates in-vitro as well as in-vivo.  Many studies have been undertaken in 
order to further characterize the effects of the I359L substitution on metabolism.  For 
example, Takanashi et. al., have shown by using yeast expressed CYP2C9.3 and seven 
substrates, that this variant form reduces the intrinsic clearance of substrates by reducing 
Vmax as well as increasing Km albeit to different degrees, depending on the substrate 
(Takanashi et al., 2000).  In order to demonstrate in-vivo consequences of the CYP2C9.3 
variant, Steward et. al., described a homozygous *3*3 patient that was receiving a 
warfarin dose of 0.5 mg/day, which is substantially lower than the control patients’ dose 
of 4-8 mg/day (Steward et al., 1997).   
 The CYP2C9.4 variant has a threonine residue in place of the isoleucine residue at 
position 359 (Imai et al., 2000).  The change is a result of a substitution of thymine for 
cytosine at nucleotide 1076 (Imai et al., 2000).  As with the CYP2C9.3 variant, this 
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amino acid change is thought to be in the active site (Gotoh, 1992).  The fact that the 
hydrophilic threonine residue is substituted for the hydrophobic isoleucine residue may 
play a role in the altered metabolism of substrates.  The I359T mutation is very rare and 
was found in Japanese epileptic patients with decreased phenytoin clearance (Imai et al., 
2000).  In another study, this variant was found in less than 2% of Japanese subjects, and 
the in-vitro intrinsic clearance of CYP2C9.4 was found to be about 5 fold lower than 
CYP2C9.1 for diclofenac oxidation (Ieiri et al., 2000).  The effect on Vmax/Km was 
mainly due to a lowered Vmax, with little effect on Km (Ieiri et al., 2000).  The in-vivo 
effects of CYP2C9.4 have not yet been well characterized, but were found to be similar 
to CYP2C9.3 in one patient for a single dose of phenytoin (Ieiri et al., 2000). 
 The CYP2C9.5 variant has a glutamate residue in place of an aspartate residue at 
position 360 as a result of a cytosine to guanine change at nucleotide 1080 (Dickmann et 
al., 2001).  Approximately 3% of the African-American population are heterozygous, 
*1*5, for this variant with no subjects being identified as homozygous, *5*5 (Dickmann 
et al., 2001).  The CYP2C9*5 allele was also recently found in 1% of a black African 
population from Tanzania (Yasar et al., 2002).  So far, no Caucasian or Asian subjects 
have been genotyped with a *5 allele.  Again, the site of the amino acid change is in SRS 
5, so this change is presumed to cause an alteration of the metabolism of CYP2C9 
substrates (Gotoh, 1992).  As with CYP2C9.3, the amino acid change is a minor one.  
The glutamate residue of the mutant has one extra carbon in the side chain compared to 
the aspartate in the wild type form, possibly making the active site smaller and causing 
greater steric hinderance or affecting protein folding.  Dickmann et al. have shown that 
the Vmax/Km for lauric acid, diclofenac, and S-warfarin metabolism is 9%, 18%, and 8% 
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compared to wild type, respectively (Dickmann et al., 2001).  The effect on Vmax/Km 
was mainly due to an increase in Km with little effect on Vmax for these substrates.  
Since this variant was discovered recently, there has not yet been any in-vivo studies 
reported.   
 The most recently discovered allelic variant, CYP2C9.6, occurs as a result of an 
adenine base pair deletion at nucleotide 818, creating a premature stop codon (Kidd et al., 
2001).  The outcome of which is a truncated protein that is inactive.  This variant was 
found in one African-American subject who experienced an adverse reaction to 
phenytoin due to reduced clearance of the drug from the body (Kidd et al., 2001).  
Further genotyping studies have revealed that one of 158 alleles identified in 79 African-
American subjects contained the deletion (Kidd et al., 2001).  No subjects in a French 
Caucasian population were found to have contained the mutation (Kidd et al., 2001).  
Further investigation of the prevalence of this variant in the population is needed. 
 A number of substrates have been used as in-vitro and in-vivo probes for 
CYP2C9 activity.  Good probe substrates are readily metabolized, stable enough for 
quantification, and are only metabolized by one P450 isoform, which is especially 
important when dealing with in-vivo studies or in-vitro studies using human liver 
microsomes that contain all of the isoforms.  Flurbiprofen is a NSAID that is used as a 
CYP2C9 probe substrate in both in-vivo and in-vitro studies, and has been shown to be 
4′-hydroxylated solely by CYP2C9 and exhibits Michaelis-Menten type kinetics (Tracy et 
al., 1995;Tracy et al., 1996).  The NSAID, naproxen, is another probe substrate often 
used for studying CYP2C9 activity.  Although CYP1A2 is involved in the metabolism of 
naproxen, CYP2C9 is mostly responsible (Miners et al., 1996;Tracy et al., 1997).  In 
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human liver microsomes, a biphasic kinetic profile is evident suggesting a role for more 
than one P450 isoform (Tracy et al., 1997).  However, when incubated with purified 
CYP2C9 enzyme, naproxen metabolism still exhibits a biphasic kinetic profile suggesting 
that more than one productive binding region exists for naproxen within the enzyme, 
making naproxen an interesting compound for study (Hutzler et al., 2001;Korzekwa et 
al., 1998;Tracy et al., 2002). 
 Not only is CYP2C9 mediated metabolism affected by amino acid substitutions of 
the allelic variants, but also by chemical effectors.  Normally when more than one 
substrate is present, inhibition occurs.  However, the opposite is true when dapsone is co-
incubated with certain substrates and CYP2C9.  Dapsone is an antibacterial agent used 
mainly for the treatment of Pneumocystis carinii infections in AIDS patients.  The 
presence of dapsone increases the CYP2C9 mediated metabolism of flurbiprofen, 
naproxen, and piroxicam metabolism (Hutzler et al., 2001;Hutzler et al., 2002;Korzekwa 
et al., 1998).  The activation, or increase in metabolism due to the presence of another 
substrate is also known as positive heterotropic cooperativity.  This phenomenon has only 
recently been described and has been studied in CYP3A4 as well as CYP2C9 (Galetin et 
al., 2002;Nakamura et al., 2002;Shou et al., 1994). 
 While the effects of allelic variants and the presence of dapsone on CYP2C9 
mediated metabolism have been studied, the effects of dapsone activation on the allelic 
variants of CYP2C9 have not.  We hypothesized that since the CYP2C9 allelic variants 
show differential rates of metabolism, they will also show differential degrees of dapsone 
activation.  Six concentrations of dapsone and six concentrations of substrate, either 
flurbiprofen or naproxen, were co-incubated with purified CYP2C9.1, CYP2C9.2, 
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CYP2C9.3, or CYP2C9.5 that were reconstituted with dilauroylphosphatidylcholine 
vesicles, NADPH Reductase, and cytochrome b5.  This resulted in six kinetic profiles 
containing six data points each, and the estimation of six sets of kinetic parameters (i.e. 
Vmax and Km) for each variant form and substrate studied.  Enzyme efficiencies 
(Vmax/Km) were calculated from the estimates and were used as the basis of comparison 
for dapsone activation. 
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CHAPTER II 
 
2. Materials and Methods 
 10
 Chemicals and Reagents.  S-Flurbiprofen, 4′-hydroxyflurbiprofen, and 2-fluoro 4-
biphenyl acetic acid were gifts from Pharmacia Corporation (Kalamazoo, MI).  S-
Naproxen and desmethylnaproxen were gifts from Syntex Laboratories (Palo Alto, CA).   
Octyl-Sepharose CL-4B, sodium cholate, dapsone, antibiotic and antimycotic solution 
containing 10,000 units of penicillin G, 10 mg streptomycin, and 25µg amphotericin B 
per mL, NADPH, dilauroylphosphatidylcholine, and PMSF were purchased from Sigma-
Aldrich (St. Louis, MO).  Acetonitrile, potassium phosphate, EDTA, and dithiothreitol 
were purchased from Fisher Scientific (Pittsburgh, PA).  Emulgen 911 was obtained from 
Kao Atlas (Japan).  Ceramic hydroxyapatite Type I was purchased from Bio-Rad 
Laboratories (Hercules, CA).  Hy-Q SFX insect media was purchased from HyClone 
Laboratories (Logan, UT).  All other chemicals were purchased from commercial sources 
and were of the highest purity available. 
 Mutagenesis and Vector Construction. The construction and amplification of the 
baculovirus vectors necessary for production of the recombinant CYP2C9 alellic variants 
were carried out according to established methods (Dickmann et al., 2001;Haining et al., 
1996) and the vectors were provided to us by Dr. Robert Haining and Dr. Allan Rettie. 
 Enzyme Expression.  The expression of recombinant human CYP2C9 and variants 
was performed according to the previous methods of Haining et al., (Haining et al., 
1996).  Trichoplusia ni cells were grown with Hy-Q SFX insect media supplemented 
with 10% heat inactivated fetal bovine serum and 1% antibiotic antimycotic solution on 
10x100mm culture dishes at 27° C.  For expressing CYP2C9 and its variants, the T. ni 
cells were scaled up to 250 mL suspension cultures in 2 L flasks and spun on a magnetic 
stir plate at 250 RPM to prevent cell clumping and ensure an adequate oxygen supply.  
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When the viable cell density reached 1-2 x 106 cells/mL, the cells were infected with the 
appropriate baculovirus.  Two days post infection, supplemental hemin, dissolved in 
NH4OH, was added to the suspension cultures to give a final concentration of 1-5 µg/mL.  
Three days after infection, the suspension culture was centrifuged at 3,000 RPM for 20 
minutes. The pelleted cells were then washed once with storage buffer and re-centrifuged 
at 3,000 RPM for 15 minutes.  The cell pellet was then stored at -80°C until purification.            
 Enzyme Purification.  The purification of recombinant human CYP2C9 and 
variants was performed according to the previous methods of Haining et al., (Haining et 
al., 1996).  All steps were carried out at 4°C.  The cell pellet was homogenized with 5-10 
passes of a glass/Teflon homogenizer with Solubilization Buffer [50mM potassium 
phosphate pH 7.4, 20% glycerol, 1 mM EDTA, 0.4 mM PMSF, 1 mM DTT, 1.0% 
sodium cholate] at a concentration of 1 mL buffer/nmol P450.  The homogenized pellet 
was then stirred for 60 minutes to further solubilize the membrane-bound P450’s.  The 
mixture was then centrifuged at 100,000g for 60 minutes to remove insoluble cell debris.  
The supernatant was then loaded at 60 mL/hr onto a 2.5x20 cm Octyl-Sepharose CL-4B 
(1 mL/nmol P450) column pre-equilibrated with at least 10 column volumes of Buffer A 
[50 mM potassium phosphate pH 7.4, 20% glycerol, 1 mM EDTA, 0.2 mM PMSF, 1mM 
DTT, 0.1 M NaCl, 0.5% sodium cholate].  The P450 appeared on the column as a red 
band.  The column was then washed with Buffer A + 0.1% Emulgen 911 until the red 
band moved approximately 2/3 down the column.  The P450 was then eluted with Buffer 
A + 1.0% Emulgen 911.  The P450 containing fractions were collected and then diluted 2 
fold with Buffer B [25 mM potassium phosphate pH 7.4, 20% glycerol, 1 mM EDTA, 0.5 
mM DTT, 0.5% Emulgen 911] and dialyzed overnight against Buffer B.  The dialyzed 
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fractions were then loaded at 80 ml/hr onto a 1.0x15 cm ceramic hydroxyapatite (1 
mL/100 nmol P450) column pre-equilibrated with Buffer B.  The P450 appeared as a red 
band on the hydroxyapatite.  The column was then washed with Buffer C [25 mM 
potassium phosphate pH 7.4, 20% glycerol, 1 mM EDTA, 0.5 mM DTT, 0.1% sodium 
cholate] until the UV absorbance at 280nm was less than 0.2 in order to ensure the 
removal of the Emulgen 911.  The P450 was then eluted with Buffer D [500mM 
potassium phosphate pH 7.4, 20% glycerol, 1 mM EDTA, 0.5 mM DTT].  The fractions 
were collected, pooled and dialyzed overnight against two changes of Buffer E [50 mM 
potassium phosphate pH 7.4, 20% glycerol, 1 mM EDTA].  500 µL aliquots were then 
stored in microcentrifuge tubes at -80°C until further use.                   
 Enzyme Reconstitution.  Dilauroylphosphatidylcholine was weighed out and 
hydrated in 50 mM potassium phosphate buffer pH 7.4 to make a 1 mg/mL solution. The 
solution sat for one hour in order to allow for formation of lipid vesicles.  The vesicles 
were then extruded through a 200 nm pore-sized membrane to make the vesicles uniform 
in size.  The CYP2C9 variant of choice and P450 NADPH Reductase were then gently 
mixed in a 1:2 ratio in a microcentrifuge tube with the end of the pipette tip and allowed 
to sit for five minutes.  The lipid vesicles were then added and the mixture again was 
allowed to equilibrate for five minutes.  Finally, cytochrome b5 was added in a 1:1 ratio 
with the P450 and the entire mixture was left to sit for five minutes.  The mixture was 
then given a short centrifugation in order to get any of the reconstituted enzyme mixture 
off the sides of the tube and into the rest of the solution.  The enzyme prep was then 
added to the incubation mixture containing substrate and effector.      
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 Incubation Conditions. Incubations were carried out according to the previous 
methods of Tracy et al., (Tracy et al., 2002).  Incubation mixtures contained 5-20 pmol of 
purified enzyme, NADPH reductase, and cytochrome b5 in a 1:2:1 ratio, reconstituted 
with dilauroylphosphatidylcholine vesicles extruded through a 200nm pore sized 
membrane.   Six concentrations of substrate, either 2-300 µM (S)-flurbiprofen or 10-1800 
µM (S)-naproxen, were incubated with six concentrations of dapsone, 0-100 µM, for 20 
minutes at 37°C in 50 mM potassium phosphate buffer pH 7.4 at a final volume of 200 
µL.  The reactions were initiated by the addition of 1 mM NADPH after a 3 minute 
preincubation.  The reactions were quenched by the addition of 200 µL acetonitrile 
containing internal standard, 180 ng/mL of 2-fluoro-4-biphenylacetic acid for (S)-
flurbiprofen or 500 ng/mL of 2-fluoro-4-biphenylacetic acid for (S)-naproxen.  Following 
quenching, 40 µL of half strength H3PO4 was added to the reaction mixtures for both 
substrates. Samples were then centrifuged at 10,000 rpm for 4 minutes, placed into 
autosampler vials, and 5-50 µL were injected onto the HPLC system. 
 HPLC Analysis.  The HPLC system consisted of a Waters 501 pump module, a 
Waters 717 autosampler, and a Waters 470 fluorescence detector.  For both metabolites, 
the mobile phase was pumped through a Brownlee Spheri-5 C18 4.6- x 100-mm column at 
1 mL/minute.  For quantification of 4′-hydroxyflurbiprofen, the detector was set at an 
excitation wavelength of 260 nm and an emission wavelength of 320 nm, and the mobile 
phase consisted of 45:55 acetonitrile:20 mM potassium phosphate pH 3.0.  The retention 
times for 4′-hydroxyflurbiprofen and the internal standard were approximately 2.6 and 
5.6 minutes, respectively.  For quantification of desmethylnaproxen, the detector was set 
at an excitation wavelength of 230 nm and an emission wavelength of 340 nm, and the 
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mobile phase consisted of 40:60 acetonitrile:20 mM potassium phosphate pH 3.0.  The 
retention times for desmethylnaproxen and the internal standard were approximately 2.3 
and 9.6 minutes, respectively. 
 Data Analysis.  Kinetic parameters for the substrates were estimated by nonlinear 
regression analysis using Sigma Plot 7.0. Data were fit to the Michaelis-Menten equation, 
SK
SV
v
m +
⋅= )( max , a linear equation, ( )SCLv int= , or a biphasic equation, 
( ) ( )
SK
SCLSVv
m
m
+
⋅+⋅=
1
2
int1 . 
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CHAPTER III 
 
3. Dapsone Activation of CYP2C9 Allelic Variants 
 
 16
3.1 Introduction 
 
Differences in metabolism among allelic variants of cytochromes P450 are 
becoming increasingly important as knowledge is being gained about the in-vitro and in-
vivo consequences of the single nucleotide polymorphisms which result in amino acid 
substitutions.  One polymorphic P450 of importance is CYP2C9, because it is involved in 
the metabolism of a wide range of substrates, including S-warfarin, phenytoin, 
tolbutamide, as well as a number of NSAIDS (Leemann et al., 1993;Rettie et al., 
1992;Rodrigues et al., 1996;Tracy et al., 1996;Veronese et al., 1991a;Zhao et al., 1992).  
When assessing the effects of CYP2C9 allelic variants, the substrates of most concern are 
the low therapeutic index drugs, S-warfarin and phenytoin, because individuals 
expressing an allelic variant may exhibit reduced clearance of these agents (Furuya et al., 
1995;Hashimoto et al., 1996;Rettie et al., 1994). 
Six allelic variants of CYP2C9 have been described to date, including CYP2C9.1 
(wild type), CYP2C9.2 (R144C), CYP2C9.3 (I359L), CYP2C9.4 (I359T), CYP2C9.5 
(D360E), and CYP2C9.6 (818delA).  Of the six, the most well characterized are 
CYP2C9.1, CYP2C9.2, and CYP2C9.3.  Compared to the wild type enzyme, CYP2C9.2 
and CYP2C9.3, found mostly in the Caucasian population, exhibit reduced metabolism of 
a number of substrates (Haining et al., 1996;Steward et al., 1997;Takanashi et al., 
2000;Yamazaki et al., 1998).  The CYP2C9.2 variant enzyme appears to reduce the 
Vmax of substrate turnover but have little effect on Km (Yamazaki et al., 1998).  
However, with the CYP2C9.3 allele, Km is increased for all studied substrates whereas 
Vmax is decreased (Takanashi et al., 2000).  Limited information is available concerning 
the rare variant, CYP2C9.4, which was found in a Japanese epileptic patient, but this 
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patient required a lower than normal dose of phenytoin (Ieiri et al., 2000).  CYP2C9.5, 
which has been shown to occur in the African-American and African populations, has 
been associated with reductions in in-vitro intrinsic clearance of a number of substrates, 
including lauric acid, S-warfarin, diclofenac, flurbiprofen, naproxen, and piroxicam. 
(Dickmann et al., 2001;Tracy et al., 2002) but in vivo consequences of this amino acid 
change are to date unknown.  Interestingly, this allele was found in 1 % of a Tanzanian 
population but not in an Ethiopian population (Yasar et al., 2002).  The most recently 
described variant, CYP2C9.6, was identified in an African-American subject exhibiting 
phenytoin toxicity (Kidd et al., 2001).  Since this protein is truncated as a result of a 
premature stop codon, it is inactive. 
Dapsone has been shown to activate the metabolism of CYP2C9 substrates, such 
as flurbiprofen, naproxen, and piroxicam (Hutzler et al., 2001;Hutzler et al., 
2002;Korzekwa et al., 1998).  This activation results in a decrease in the Km and an 
increase in the Vmax of the CYP2C9 enzyme causing an increase in efficiency of the 
enzyme and substrate turnover.  Since amino acid changes in key residues, such as those 
found in the allelic variants, alter rates of metabolism, these substitutions may also affect 
the degree of activation observed since it has been proposed that the activator must also 
bind within the enzyme active site to cause its effect.  However, the degree of dapsone 
mediated activation of CYP2C9 allelic variants has not been assessed.  Using 
flurbiprofen and naproxen as probe substrates, the effects of dapsone on CYP2C9.1, 
CYP2C9.2, CYP2C9.3, and CYP2C9.5 mediated metabolism were studied to determine 
whether the degree of enzyme activation is dependent on the enzyme allelic variant being 
studied. 
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3.2 Materials and Methods 
 
 Chemicals and Reagents.  S-Flurbiprofen, 4′-hydroxyflurbiprofen, and 2-fluoro 4-
biphenyl acetic acid were gifts from Pharmacia Corporation (Kalamazoo, MI).  S-
Naproxen and desmethylnaproxen were gifts from Syntex Laboratories (Palo Alto, CA).  
Dapsone, NADPH, and dilauroylphosphatidylcholine were purchased from Sigma-
Aldrich (St. Louis, MO).  Acetonitrile and potassium phosphate were purchased from 
Fisher Scientific (Pittsburgh, PA).  Human P450 oxidoreductase and human cytochrome 
b5 were purchased from Pan Vera LLC (Madison, WI).  All other chemicals were 
purchased from commercial sources and were of the highest purity available. 
 Enzyme Construction and Expression. Mutagenesis and vector construction of the 
wild type enzyme, the R144C (*2), I359L (*3), and the D360E (*5) variants were carried 
out according to previously established methods (Dickmann et al., 2001;Haining et al., 
1996).  Proteins were expressed using a baculovirus mediated expression system in 
Trichoplusia ni cells and carried out according to the methods of Haining et al., (1996).  
Protein purification was performed as described previously (Dickmann et al., 2001). 
 Incubation Conditions. Incubations were carried out according to the methods of 
Tracy et al., (2002).  Incubation mixtures contained 5-20 pmol of purified enzyme, 
NADPH reductase, and cytochrome b5 in a 1:2:1 ratio, reconstituted with 
dilauroylphosphatidylcholine vesicles extruded through a 200 nm pore sized membrane.   
Six concentrations of substrate, either 2-300 µM (S)-flurbiprofen or 10-1800 µM (S)-
naproxen, were incubated with six concentrations of dapsone, 0-100µM, for 20 minutes 
at 37°C in 50mM potassium phosphate buffer pH 7.4 in a final volume of 200 µL.  The 
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reactions were initiated by the addition of 1 mM NADPH after a 3 minute preincubation.  
Reactions were quenched by the addition of 200 µL acetonitrile containing internal 
standard, 180 ng/mL of 2-fluoro-4-biphenylacetic acid for (S)-flurbiprofen or 500 ng/mL 
of 2-fluoro-4-biphenylacetic acid for (S)-naproxen.  Following quenching, 40µL of half 
strength H3PO4 was added to the reaction mixtures for both substrates.  Samples were 
then centrifuged at 10,000 rpm for 4 minutes, placed into autosampler vials, and 5-50 µL 
injected onto the HPLC system. 
 HPLC Analysis.  HPLC analysis was conducted as described previously (Tracy et 
al., 2002).  The HPLC system consisted of a Waters 501 pump module, a Waters 717 
autosampler, and a Waters 470 fluorescence detector.  For both metabolites, the mobile 
phase was pumped through a Brownlee Spheri-5 C18 4.6 x 100 mm column at 1 
mL/minute.  For quantification of 4′-hydroxyflurbiprofen, the detector was set at an 
excitation wavelength of 260 nm and an emission wavelength of 320 nm, and the mobile 
phase consisted of 45:55 acetonitrile:20 mM potassium phosphate pH 3.0.  The retention 
times for 4′-hydroxyflurbiprofen and the internal standard were approximately 2.6 and 
5.6 minutes, respectively.  For quantification of desmethylnaproxen, the detector was set 
at an excitation wavelength of 230 nm and an emission wavelength of 340 nm, and the 
mobile phase consisted of 40:60 acetonitrile:20 mM potassium phosphate pH 3.0.  The 
retention times for desmethylnaproxen and the internal standard were approximately 2.3 
and 9.6 minutes, respectively. 
 Data Analysis.  Kinetic parameters for the substrates were estimated by nonlinear 
regression analysis, using Sigma Plot 7.0.  Data were fit to the Michaelis-Menten 
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3.3 Results 
 
 Figure 3.1 depicts the best fit of the data to the standard Michaelis-Menten 
equation for dapsone activation of flurbiprofen 4′-hydroxylation by CYP2C9.1, 
CYP2C9.2, CYP2C9.3, and CYP2C9.5.  Kinetic parameter estimates for the fits can be 
found in Table 3.1.  In the absence of dapsone, CYP2C9.1 exhibited the highest activity 
of flurbiprofen 4′-hydroxylation, followed by CYP2C9.2, CYP2C9.5, and CYP2C9.3.  In 
all of the variants, dapsone increased the metabolism of flurbiprofen.  The Vmax was 
increased roughly 2-fold while the Km was decreased 4-fold in the presence of 100 µM 
dapsone as compared to the absence of dapsone in CYP2C9.1.  Similar trends were noted 
for the other variants, although to varying degrees.  These differences in increase of 
enzymatic efficiency (Vmax/Km) among the different allelic variants in the presence of 
dapsone are presented in Table 3.3. 
 Naproxen demethylation was also activated by the presence of dapsone in all of 
the allelic variants tested (Figure 3.2).  In the cases of CYP2C9.1 in the presence of 0-5 
µM dapsone and CYP2C9.2 in the presence of 0-2 µM dapsone, the resulting data were 
best fit to a biphasic equation, resulting in estimates of  Vmax, Km and  CLint describing 
the biphasic nature of the data.  For CYP2C9.3 and CYP2C9.5 in the presence of 0-2 µM 
dapsone the data were best fit to a linear equation with CLint representing the slope of the 
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line, since no hyperbolic character was noted within the substrate concentration range 
studied.  The remaining data for each of the variants in the presence of 10-100 µM 
dapsone (CYP2C9.1) or 5-100 µM dapsone (CYP2C9.2, CYP2C9.3, CYP2C9.5) were 
best fit to the Michaelis-Menten equation.  Kinetic parameter estimates are represented in 
Table 3.2.  As with flurbiprofen, dapsone increased the Vmax of naproxen demethylation, 
while the Km was decreased for all variants.  As implied above, the rates of naproxen 
demethylation became increasingly hyperbolic with increasing dapsone concentration in 
the case of all CYP2C9 variants.  As illustrated with flurbiprofen, the efficiency 
(Vmax/Km) of CYP2C9 mediated naproxen demethylation increased to varying degrees 
depending on the allelic variant studied (Table 3.3). 
 
3.4 Discussion 
 
 Many factors can confound formulation of accurate in-vitro/in-vivo correlations, 
including atypical kinetics, such as positive heterotropic cooperativity or activation, as 
well as the effects of allelic variants on metabolism.  CYP2C9 exhibits all of these 
characteristics. We have previously demonstrated that dapsone can activate CYP2C9 
mediated metabolism of flurbiprofen and naproxen (Hutzler et al., 2001) and that allelic 
variants of CYP2C9 exhibit lower substrate turnover (Tracy et al., 2002).  However, 
whether allelic variants exhibit differential activation by enzyme effectors such as 
dapsone was unknown.  We hypothesized that because allelic variants of this enzyme 
exhibit reduced turnover of substrate, they would also be affected differentially by the 
effector, dapsone, and thus exhibit differential activation of CYP2C9 mediated 
metabolism as compared to wild type enzyme.  Thus we studied the effects of dapsone on 
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flurbiprofen and naproxen metabolism by R144C (CYP2C9.2), I359L (CYP2C9.3), and 
the D360E (CYP2C9.5) variants of CYP2C9 and compared the results to the wild type 
enzyme.  Our results suggest that the substitutions alter the degree of dapsone activation, 
as measured by the increase in enzyme efficiency (Vmax/Km) of flurbiprofen 4′-
hydroxylation and naproxen demethylation to different extents, not only compared to the 
wild type enzyme, but compared to one another as well.  
 Flurbiprofen was used to examine dapsone activation of CYP2C9 allelic variants 
because its metabolism has been shown to be activated by dapsone with the wild type 
enzyme and it exhibits typical Michaelis-Menten kinetics.  In the absence of dapsone, 
CYP2C9.2, CYP2C9.3, and CYP2C9.5 exhibited a Vmax/Km ratio (measure of enzyme 
efficiency) for flurbiprofen 4′-hydroxylation that was 70%, 4%, and 10% of CYP2C9.1 
activity, respectively.  In all variants, Km was reduced and Vmax increased in the 
presence of dapsone, although to different extents depending on the allelic variant being 
studied.  In the case of flurbiprofen hydroxylation, the efficiency of the CYP2C9.3 
variant was increased greater than 6-fold more in the presence of dapsone than was the 
efficiency of the wild type enzyme whereas the efficiency of the CYP2C9.2 and 
CYP2C9.5 variants were increased 4.5- and 3-fold more than was the wild type enzyme.  
These findings suggest that these amino acids play a key role not only in flurbiprofen 
hydroxylation but also are in some way involved in the extent of dapsone activation. 
However, the role they play in activation and increase in enzyme efficiency is not clearly 
defined.  The substituted residues may change substrate and/or effector binding directly, 
alter folding of the protein or increase the efficiency of the enzyme through other 
unknown mechanisms. 
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 Naproxen was also tested for differential effects of dapsone activation of the 
allelic variants of CYP2C9, because naproxen exhibits atypical kinetics presumably due 
to occupation of multiple binding regions within the CYP2C9 active site (Hutzler et al., 
2001;Korzekwa et al., 1998).  Additionally, co-incubation with dapsone results in the 
conversion of the biphasic kinetic profile to a hyperbolic kinetic profile (Hutzler et al., 
2001).  In the absence of dapsone, CYP2C9.1 and CYP2C9.2 mediated naproxen 
demethylation was biphasic in nature, and CYP2C9.3 and CYP2C9.5 mediated naproxen 
demethylation had a linear kinetic profile over the concentration ranges that were studied.  
Because of the differences in kinetic profiles observed, direct comparison of kinetic 
parameters among the allelic variants is complicated.  However, in each of the variants 
and wild type enzyme, at 10 µM dapsone concentrations and higher, the data were best fit 
with a hyperbolic equation (i.e., normalization of kinetics) allowing comparison of 
kinetic parameters.  As with flurbiprofen, dapsone increased the Vmax and reduced the 
Km for naproxen demethylation in all cases.  Again, however, there are differences in 
efficiency increase among the variants and the rank order was different than observed 
with flurbiprofen hydroxylation.  For naproxen demethylation, the CYP2C9.5 variant 
exhibited the greatest increase in enzyme efficiency (Vmax/Km) with lesser increases 
noted with the CYP2C9.2 and CYP2C9.3 variants.  However, it should be re-emphasized 
that these comparisons are somewhat confounded by the change in kinetic profile.  This 
normalization of kinetics has been hypothesized to be due to dapsone filling one of the 
binding regions in the active site of the enzyme and thus causing naproxen to occupy 
only one site (instead of the usual two) and now behaving in a hyperbolic kinetic manner 
(Hutzler et al., 2001).  This “normalization” of kinetic profile has also been observed 
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with the CYP3A4 enzyme by Nakamura and colleagues who demonstrated that 
androstenedione could activate CYP3A4 mediated carbamazepine metabolism and 
convert the kinetic profile from a sigmoidal to a hyperbolic kinetic form (Nakamura et 
al., 2002).  
 CYP2C9.2 has been associated with reduced metabolism both in-vitro and in-
vivo, mainly by reducing the Vmax, with little effect on Km.  Because of this, amino acid 
position 144 is not thought to be in the active site of the enzyme, though the publishing of 
the CYP2C9 crystal structure may provide additional insight.  Crespi and Miller have 
implicated this substitution in reducing the interaction of the P450 with NADPH 
reductase, which is essential for electron flow necessary for the oxidation of substrates 
(Crespi and Miller, 1997).  This effect could be due to the fact that the side chain of 
arginine is charged at pH 7.4, making an electrostatic contact with the reductase, whereas 
the cysteine side chain is polar, but not charged.  However, in this study, the presence of 
dapsone decreased the Km for both flurbiprofen 4′-hydroxylation and naproxen 
demethylation for CYP2C9.2.  Thus, it is unclear whether this residue does in fact play a 
role in substrate or effector binding, causes a change in protein folding or in conjunction 
with dapsone inhibits enhanced electron flow through the enzyme. 
 The CYP2C9.3 variant has a leucine residue in place of an isoleucine residue at 
amino acid position 359 and the CYP2C9.5 variant contains a glutamate in place of an 
aspartate at position 360.  Both position 359 and 360 have been purported to be in 
substrate recognition site (SRS) 5 and may play a role in substrate binding (Gotoh, 1992).  
Though these amino acid changes appear minor, the substitution may alter the size or 
shape of the binding pocket and cause differences in steric hinderance compared to the 
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wild type protein, resulting in reductions in the metabolism of substrates or effector 
binding, or the protein may take on a different shape as a result of a variation in protein 
folding with the substituted amino acid.  Regardless, these variants appear to be affected 
differentially by dapsone as compared to the wild type enzyme and thus play a role in 
activation of the enzyme. 
 Not only were the effects of dapsone activation variant specific, they were also 
substrate specific.  Effects of allelic variants on metabolism have been shown to be 
substrate specific (Takanashi et al., 2000;Tracy et al., 2002).  In this study, flurbiprofen 
4′-hydroxylation was minimally activated in the presence of 2-10 µM dapsone, while 
naproxen demethylation was activated to a greater extent at lower dapsone 
concentrations.  Also, the maximal velocity of naproxen demethylation was increased to a 
level double that of flurbiprofen 4′-hydroxylation with the exception of CYP2C9.2, 
which was similar.  By testing a number of steroids with a variety of substrates, 
Nakamura et. al., demonstrated that there are substrate specific differences in effects of 
endogenous steroids on CYP3A4 mediated metabolism (Nakamura et al., 2002).  
Similarly, Galetin et. al., showed that quinidine differentially activated or inhibited 
CYP3A4 mediated metabolism depending on the substrate used (Galetin et al., 2002).  
We have shown that dapsone activates CYP2C9 mediated metabolism to different extents 
based on the substrate being studied. 
 It is also interesting to note that in all cases, dapsone was able to activate the 
turnover of substrate to a level similar to or greater than the level achieved by CYP2C9.1 
in the absence of dapsone.  As stated previously, CYP2C9.2, CYP2C9.3, and CYP2C9.5 
exhibited a Vmax/Km ratio that was 70%, 4%, and 10%, respectively, that of the wild 
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type enzyme in the absence of dapsone.  However, when comparing the Vmax/Km ratio 
for flurbiprofen 4′-hydroxylation for CYP2C9.2, CYP2C9.3, and CYP2C9.5 in the 
presence of 100µM dapsone to CYP2C9.1 in the absence of dapsone, they have a 
Vmax/Km ratio that is 2190%, 188%, and 220% of the wild type enzyme in the absence 
of dapsone.  For naproxen demethylation, it is more difficult to compare the kinetic 
parameters due to the different kinetic profiles for the absence and presence of dapsone.  
However, from Figure 3.2, it is clear that naproxen demethylation is increased to a level 
greater than that of the wild type for all of the allelic variants studied, especially at lower 
concentrations of naproxen.  Whether this ability to convert a “poor” metabolizer to an 
extensive metabolizer state in vitro can be translated to the in vivo situation remains to be 
studied.  However, it does raise intriguing possibilities in terms of the potential ability to 
normalize patients with respect to drug metabolism capacity.      
 In summary, the ability of dapsone to activate CYP2C9 mediated metabolism is 
both allelic variant and substrate dependent.  Dapsone co-incubation reduces the Km and 
increase the Vmax of both flurbiprofen 4′-hydroxylation and naproxen demethylation 
resulting in an increase in the overall efficiency of the enzyme with greater effects being 
noted in the allelic variants as compared to wild type enzyme.  These findings 
demonstrate that the degree of drug-drug interaction may be influenced by an individual’s 
genotype. 
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Figure 3.1  Dapsone activation of flurbiprofen 4′-hydroxylation by (A) CYP2C9.1, (B) 
CYP2C9.2, (C) CYP2C9.3, and (D) CYP2C9.5. 
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Figure 3.2  Dapsone activation of naproxen demethylation by (A) CYP2C9.1, (B) 
CYP2C9.2, (C) CYP2C9.3, and (D) CYP2C9.5. 
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Table 3.1  Kinetic Parameter Estimates for Flurbiprofen 4′-hydroxylation. 
 
Dapsone V max K m V max /K m V max K m V max /K m V max K m V max /K m V max K m V max /K m
µM pmol/min/pmol P450 µM µl/min/pmol P450 pmol/min/pmol P450 µM µl/min/pmol P450 pmol/min/pmol P450 µM µl/min/pmol P450 pmol/min/pmol P450 µM µl/min/pmol P450
0 3.25 (0.28) 33.5 (9.35) 0.10 2.13 (0.06) 29.2 (2.68) 0.07 0.76 (0.03) 170 (15.7) 0.004 1.32 (0.11) 93.1 (21.1) 0.01
2 3.18 (0.25) 29.9 (7.87) 0.11 2.29 (0.06) 23.8 (2.18) 0.10 0.89 (0.05) 133 (15.6) 0.007 1.19 (0.14) 72.5 (24.0) 0.02
5 3.29 (0.32) 25.6 (8.64) 0.13 2.80 (0.09) 15.2 (1.74) 0.18 1.13 (0.03) 96.1 (7.19) 0.012 1.30 (0.20) 63.7 (28.6) 0.02
10 3.52 (0.26) 26.0 (6.46) 0.14 3.42 (0.08) 10.8 (0.94) 0.32 1.46 (0.02) 73.5 (2.72) 0.020 1.30 (0.24) 58.9 (32.5) 0.02
50 4.48 (0.27) 8.48 (2.01) 0.53 5.59 (0.11) 5.00 (0.41) 1.12 3.85 (0.08) 41.4 (2.66) 0.093 2.75 (0.40) 20.3 (10.4) 0.14
100 5.72 (0.28) 7.26 (1.45) 0.79 6.40 (0.20) 2.92 (0.47) 2.19 4.47 (0.13) 23.8 (2.33) 0.188 3.58 (0.20) 16.1 (3.31) 0.22
CYP2C9.1 CYP2C9.2 CYP2C9.3 CYP2C9.5
 
 
Parameter estimates are reported as the estimate (standard error of the estimate) resulting from nonlinear regression of the data. 
 
 
 
 30
Table 3.2  Kinetic Parameter Estimates for Naproxen Demethylation.  
 
Dapsone V max K m CLint V max K m CLint V max K m CLint V max K m CLint
µM pmol/min/pmol P450 µM µl/min/pmol P450 pmol/min/pmol P450 µM µl/min/pmol P450 pmol/min/pmol P450 µM µl/min/pmol P450 pmol/min/pmol P450 µM µl/min/pmol P450
0 2.58 (0.36) 248 (59.7) 0.0020 (0.0001) 0.70 (0.12) 122 (54.3) 0.0002 (0.0001) - - 0.0013 (0.0001) - - 0.0017 (0.0000)
2 5.40 (0.97) 408 (120) 0.0006 (0.0004) 1.15 (0.12) 132 (35.5) 0.0000 (0.0001) - - 0.0019 (0.0000) - - 0.0020 (0.0001)
5 6.75 (0.52) 288 (42.6) 0.0003 (0.0002) - - - - - - - - -
Dapsone V max K m V max /K m V max K m V max /K m V max K m V max /K m V max K m V max /K m
µM pmol/min/pmol P450 µM µl/min/pmol P450 pmol/min/pmol P450 µM µl/min/pmol P450 pmol/min/pmol P450 µM µl/min/pmol P450 pmol/min/pmol P450 µM µl/min/pmol P450
5 - - - 1.64 (0.04) 94.3 (11.2) 0.017 8.85 (1.73) 2292 (699) 0.004 7.60 (0.31) 1768 (120) 0.004
10 7.68 (0.16) 218 (16.9) 0.035 2.02 (0.06) 76.6 (10.9) 0.026 11.6 (1.79) 1909 (482) 0.006 7.48 (0.70) 1266 (223) 0.006
50 10.5 (0.17) 72.0 (5.83) 0.146 4.48 (0.12) 32.8 (5.17) 0.137 11.5 (0.65) 357 (61.6) 0.032 13.2 (0.92) 375 (78.5) 0.035
100 10.7 (0.32) 44.2 (7.49) 0.242 4.52 (0.46) 17.7 (11.7) 0.255 14.4 (0.45) 289 (29.7) 0.050 12.7 (0.74) 144 (35.9) 0.088
CYP2C9.1 CYP2C9.2 CYP2C9.3 CYP2C9.5
 
 
Parameter estimates are reported as the estimate (standard error of the estimate) resulting from nonlinear regression of the data. 
Table is split into biphasic (CYP2C9.1 and CYP2C9.2) and linear (CYP2C9.3 and CYP2C9.5) fits of the data (TOP) and Michaelis-
Menten fits of the data (BOTTOM). 
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Table 3.3  Percent increase in efficiency (Vmax/Km) of metabolism due to dapsone 
activation. 
 
Variant Flurbiprofen Naproxen
CYP2C9.1 690% 591%
CYP2C9.2 3029% 1400%
CYP2C9.3 4600% 1150%
CYP2C9.5 2100% 2100%  
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CHAPTER IV 
 
4. Summary and Conclusions 
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 To date, several allelic variants of CYP2C9 have been discovered in a number of 
diverse populations throughout the world.  With the prevalence of the variants becoming 
better known, it is important to study their effects in order to determine how they might 
affect drug metabolizing capacity and, possibly, prevent adverse drug reactions from 
occurring in patients.  It is also important to study drug interactions of these allelic forms.  
Recently, positive heterotropic cooperativity, or activation of substrate metabolism, has 
become a more frequently reported drug interaction.  There are many examples of this 
phenomenon in the literature for CYP2C9 as well as CYP3A4.  However, activation has 
not been studied in allelic variant forms of CYP2C9.    
 We have shown that dapsone activates flurbiprofen and naproxen metabolism by 
the CYP2C9 allelic variants to different extents.  In all cases, the increase in efficiency 
(Vmax/Km) was greater in the variants as compared to wild type enzyme.  In previous 
work, our lab has offered evidence of dapsone binding in the active site along with the 
substrate molecule causing the substrate to bind more productively. The results in this 
work also imply this to be the case, since the presence of dapsone increased the 
metabolism of flurbiprofen and naproxen for all the allelic forms studied and caused 
naproxen demethylation to take on a hyperbolic character, possibly by filling one of the 
two binding sites thought to exist in CYP2C9 for naproxen.   While we have identified 
that the amino acids substitutions of the allelic variants seem to play a role in dapsone 
activation, it is still unclear what that role may be. The amino acid substitutions may alter 
substrate or effector binding directly, or may alter the folding of the protein changing the 
characteristics of the active site.  However, other possibilities may exist, and there is an 
on-going effort to determine the nature of dapsone activation of CYP2C9 mediated 
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metabolism, as well as, the consequences on the activities of the allelic variant forms of 
CYP2C9.   
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